Physician profile
Edward J Share
NPI 1093729675
$3,877.68
in general payments reported to CMS, 2019-2025
26 companies · $22.87 in 2025
The $22.87 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,591 · 2020: $543 · 2021: $694 · 2022: $634 · 2023: $273 · 2024: $119 · 2025: $22.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $415.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $415.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,414.07 | 2019-2024 | Skyrizi, Viberzi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $761.67 | 2019-2025 | Plenvu, Xifaxan |
| Janssen Biotech, INC. | $239.08 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $237.46 | 2019-2023 | Entyvio |
| Romark Laboratories, Lc | $178.04 | 2019-2020 | |
| Daiichi Sankyo INC. | $137.74 | 2019-2022 | |
| Braintree Laboratories, INC. | $116.75 | 2019-2022 | |
| Celgene Corporation | $87.06 | 2021-2023 | Zeposia |
| Allergan, INC. | $73.45 | 2019 | |
| Pfizer INC. | $72.87 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $66.26 | 2019-2021 | |
| Micro-Tech Endoscopy USA, INC. | $64.21 | 2022 | |
| Boston Scientific Corporation | $59.89 | 2019 | |
| Alfasigma USA, INC. | $45.22 | 2020 | |
| Mauna Kea Technologies, INC. | $40.18 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $40.04 | 2019-2024 | |
| Dova Pharmaceuticals | $39.53 | 2019 | |
| Amgen INC. | $34.78 | 2022 | |
| Biofire Diagnostics, LLC | $25.75 | 2019 | |
| Aimmune Therapeutics, INC. | $25.59 | 2024 | |
| Redhill Biopharma INC. | $24.90 | 2020 | |
| Nestle Healthcare Nutrition INC. | $20.59 | 2021 | |
| Concordia Pharmaceuticals INC. | $20.00 | 2019 | |
| Gilead Sciences, INC. | $19.92 | 2019 | |
| Qol Medical, LLC | $18.40 | 2021 | |
| Shionogi INC | $14.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Share listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.